Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant butyrylcholinesterase
- Development stage
- Phase 1
- Lead developer
- AntoXa
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
**Recombinant butyrylcholinesterase (rBChE)** is a bioscavenger enzyme produced via recombinant DNA technology in systems like CHO cells or transgenic goat milk, designed to stoichiometrically bind and detoxify organophosphorus nerve agents such as sarin, soman, VX, and tabun by preventing their inhibition of acetylcholinesterase. It functions as a serine hydrolase (EC 3.1.1.8) that hydrolyzes esters including acetylcholine, cocaine, and succinylcholine, with a tetrameric form exhibiting a plasma half-life of 3-4 days extendable via PEGylation to ~44 hours for improved pharmacokinetics and bioavailability (~46% IM). Primarily developed for prophylaxis and treatment of chemical warfare agent exposure, it has shown 100% protection in animal models against multiple lethal doses without toxicity; Phase I trials confirmed safety of plasma-derived versions, with recombinant forms pursued for scalable production.[1][4][5][12][13][15]
- Brand names
- Protexia
- Other names
- recombinant human butyrylcholinesteraserBChEhuBChE
Beyond the preview
Go deeper on recombinant butyrylcholinesterase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant butyrylcholinesterase.